Enterprise Value

205.1B

Cash

2.793B

Avg Qtr Burn

-225.6M

Short % of Float

0.21%

Insider Ownership

19.56%

Institutional Own.

49.15%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
BRUKINSA (zanubrutinib) Details
Cancer, Blood cancer, Chronic lymphocytic leukemia, Small lymphocytic lymphoma

Approved

Update

BRUKINSA + obinutuzumab Details
Cancer, Follicular lymphoma

Approved

Quarterly sales

TEVIMBRA (tislelizumab) Details
Cancer, Esophageal Squamous Cell Carcinoma

Approved

Quarterly sales

Tislelizumab + chemo Details
Cancer, Gastroesophageal adenocarcinomas

PDUFA

Approval decision

TEVIMBRA (tislelizumab) Details
Esophageal Squamous Cell Carcinoma, Cancer

PDUFA

Approval decision

Phase 3

Data readout

Ociperlimab (Anti-TIGIT) Details
Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Tislelizumab Details
Cancer, Non-small cell lung carcinoma

Phase 3

Data readout

BRUKINSA + tislelizumab Details
Cancer, Hepatocellular carcinoma

Phase 3

Data readout

Phase 3

Data readout

Ociperlimab (anti-TIGIT Ab) + tislelizumab Details
Non-small cell lung carcinoma, Cervical cancer, Esophageal Squamous Cell Carcinoma, Small cell lung cancer, Cancer

Phase 2

Data readout

Phase 1/2

Data readout

BGB-16673 (BTK CDAC) Details
Cancer, B-cell malignancies

Phase 1

Data readout

BGB-A445 w/ tislelizumab Details
Renal cell carcinoma, Cancer, Bladder cancer, Melanoma

Phase 1

Update

Phase 1a

Data readout